Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1306 AI vs GD for High-Risk Soft Tissue Sarcoma
jRCTs031180003Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in soft tissue sarcoma (STS) comparing Adriamycin + Ifosfamide (AI) with Gemcitabine + Docetaxel (GD) (2 arms). Primary endpoints: Phase II: Proportion of completion of preoperative chemotherapy without progressive disease and Phase III: Overall survival. Started Jun 2014; status: completed.
02
Drugs
doxorubicinifosfamidegemcitabinedocetaxel
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCTs031180003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180003.